E-Mail
NEW YORK, NY (Feb. 26, 2021) People who took statins to lower cholesterol were approximately 50% less likely to die if hospitalized for COVID-19, a study by physicians at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian has found. Our study is one of the larger studies confirming this hypothesis and the data lay the groundwork for future randomized clinical trials that are needed to confirm the benefit of statins in COVID-19, says Aakriti Gupta, MD, a cardiologist at NewYork-Presbyterian/Columbia University Irving Medical Center and one of the co-lead authors of the study. If their beneficial effect bears out in randomized clinical trials, statins could potentially prove to be a low-cost and effective therapeutic strategy for COVID-19, adds co-lead author Mahesh V. Madhavan, MD, also a cardiologist at NewYork-Presbyterian/Columbia University Irving Medical Center.
E-Mail
DALLAS and NEW YORK - February 16, 2021 - The Heart Valve Collaboratory (HVC) announced today that the U.S. Food and Drug Administration (FDA) s Center for Devices and Radiological Health (CDRH) will participate in this collaborative community . A medical collaboratory is a forum in which multidisciplinary private and public sector members work together on medical device challenges to achieve aligned outcomes, solve shared problems, and leverage collective opportunities, in the interest of improving patient care. The FDA s Center for Devices and Radiological Health is committed to fostering innovation while encouraging development of safe and effective technologies for patients, said Bram Zuckerman, M.D., director of the Office of Cardiovascular Devices in the FDA s Center for Devices and Radiological Health. We can continue to protect and promote public health when key stakeholder groups work together. Collaborative communities can contribute to improvements in are
February 10, 2021
Upgrading a patient from an existing permanent pacemaker or implantable cardioverter-defibrillator (ICD) to a cardiac resynchronization therapy (CRT) device can be successfully and safely done in the hands of experienced operators, according to a new analysis from a large tertiary center.
When compared with patients undergoing de novo CRT implantation, the rates of procedural success and complications at 90 days were similar in patients undergoing the procedure for an upgraded device, researchers report.
The need for an upgrade is relatively common, write David Nemer, MD (Cleveland Clinic, OH), and colleagues in the January 2021 issue of
JACC: Clinical Electrophysiology. CRT is indicated for the treatment of patients with systolic congestive heart failure and electrical dyssynchrony; however, roughly 20% to 30% of all CRT devices are upgrades from an existing pacemaker and ICD. Several small studies have shown these upgraded devices also improve hemodynamic a
American Heart Association committed to support more than $230 million to achieve health equity
The American Heart Association, the leading global voluntary health organization dedicated to fighting heart disease and stroke, is making an unprecedented series of investments focused on enhancing its historic commitment to addressing the social determinants of health and the barriers to achieving health equity for all communities - urban, suburban and rural. The Association will raise and invest more than $230 million of its own funds over the next four years to support targeted initiatives and programs, while leading additional efforts to drive systemic public health change focused on removing barriers to equitable health for everyone, everywhere.